Literature DB >> 18337408

N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking.

Adam L Orr1, Shihua Li, Chuan-En Wang, He Li, Jianjun Wang, Juan Rong, Xingshun Xu, Pier Giorgio Mastroberardino, J Timothy Greenamyre, Xiao-Jiang Li.   

Abstract

Huntington's disease (HD) is caused by polyglutamine (polyQ) expansion in huntingtin (htt), a large (350 kDa) protein that localizes predominantly to the cytoplasm. Proteolytic cleavage of mutant htt yields polyQ-containing N-terminal fragments that are prone to misfolding and aggregation. Disease progression in HD transgenic models correlates with age-related accumulation of soluble and aggregated forms of N-terminal mutant htt fragments, suggesting that multiple forms of mutant htt are involved in the selective neurodegeneration in HD. Although mitochondrial dysfunction is implicated in the pathogenesis of HD, it remains unclear which forms of cytoplasmic mutant htt associate with mitochondria to affect their function. Here we demonstrate that specific N-terminal mutant htt fragments associate with mitochondria in Hdh(CAG)150 knock-in mouse brain and that this association increases with age. The interaction between soluble N-terminal mutant htt and mitochondria interferes with the in vitro association of microtubule-based transport proteins with mitochondria. Mutant htt reduces the distribution and transport rate of mitochondria in the processes of cultured neuronal cells. Reduced ATP level was also found in the synaptosomal fraction isolated from Hdh(CAG)150 knock-in mouse brain. These findings suggest that specific N-terminal mutant htt fragments, before the formation of aggregates, can impair mitochondrial function directly and that this interaction may be a novel target for therapeutic strategies in HD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18337408      PMCID: PMC2652473          DOI: 10.1523/JNEUROSCI.0106-08.2008

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  45 in total

1.  Neuropathogenic forms of huntingtin and androgen receptor inhibit fast axonal transport.

Authors:  Györgyi Szebenyi; Gerardo A Morfini; Alyssa Babcock; Milena Gould; Kimberly Selkoe; David L Stenoien; Maureen Young; Pieter W Faber; Marcy E MacDonald; Michael J McPhaul; Scott T Brady
Journal:  Neuron       Date:  2003-09-25       Impact factor: 17.173

2.  Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain.

Authors:  M DiFiglia; E Sapp; K O Chase; S W Davies; G P Bates; J P Vonsattel; N Aronin
Journal:  Science       Date:  1997-09-26       Impact factor: 47.728

3.  Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration.

Authors:  Patrick Weydt; Victor V Pineda; Anne E Torrence; Randell T Libby; Terrence F Satterfield; Eduardo R Lazarowski; Merle L Gilbert; Gregory J Morton; Theodor K Bammler; Andrew D Strand; Libin Cui; Richard P Beyer; Courtney N Easley; Annette C Smith; Dimitri Krainc; Serge Luquet; Ian R Sweet; Michael W Schwartz; Albert R La Spada
Journal:  Cell Metab       Date:  2006-10-19       Impact factor: 27.287

4.  The first 17 amino acids of Huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis.

Authors:  Erica Rockabrand; Natalia Slepko; Antonello Pantalone; Vidya N Nukala; Aleksey Kazantsev; J Lawrence Marsh; Patrick G Sullivan; Joan S Steffan; Stefano L Sensi; Leslie Michels Thompson
Journal:  Hum Mol Genet       Date:  2006-11-29       Impact factor: 6.150

5.  Mitochondrial localization of cyclooxygenase-2 and calcium-independent phospholipase A2 in human cancer cells: implication in apoptosis resistance.

Authors:  Jun-Yang Liou; Nena Aleksic; Shu-Fen Chen; Tsai-Jung Han; Song-Kun Shyue; Kenneth K Wu
Journal:  Exp Cell Res       Date:  2005-03-16       Impact factor: 3.905

6.  Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease.

Authors:  Cheryl L Wellington; Lisa M Ellerby; Claire-Anne Gutekunst; Danny Rogers; Simon Warby; Rona K Graham; Odell Loubser; Jeremy van Raamsdonk; Roshni Singaraja; Yu-Zhou Yang; Juliette Gafni; Dale Bredesen; Steven M Hersch; Blair R Leavitt; Sophie Roy; Donald W Nicholson; Michael R Hayden
Journal:  J Neurosci       Date:  2002-09-15       Impact factor: 6.167

7.  Abnormal association of mutant huntingtin with synaptic vesicles inhibits glutamate release.

Authors:  He Li; Travis Wyman; Zhao-Xue Yu; Shi-Hua Li; Xiao-Jiang Li
Journal:  Hum Mol Genet       Date:  2003-08-15       Impact factor: 6.150

8.  Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines.

Authors:  Alexander V Panov; Claire-Anne Gutekunst; Blair R Leavitt; Michael R Hayden; James R Burke; Warren J Strittmatter; J Timothy Greenamyre
Journal:  Nat Neurosci       Date:  2002-08       Impact factor: 24.884

9.  Mutant huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons.

Authors:  Diane T W Chang; Gordon L Rintoul; Sruthi Pandipati; Ian J Reynolds
Journal:  Neurobiol Dis       Date:  2006-02-09       Impact factor: 5.996

10.  Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease.

Authors:  Zhao-Xue Yu; Shi-Hua Li; Joy Evans; Ajay Pillarisetti; He Li; Xiao-Jiang Li
Journal:  J Neurosci       Date:  2003-03-15       Impact factor: 6.167

View more
  177 in total

Review 1.  Mitochondrial bioenergetics and dynamics in Huntington's disease: tripartite synapses and selective striatal degeneration.

Authors:  Jorge M A Oliveira
Journal:  J Bioenerg Biomembr       Date:  2010-06       Impact factor: 2.945

Review 2.  Energy dysfunction in Huntington's disease: insights from PGC-1α, AMPK, and CKB.

Authors:  Tz-Chuen Ju; Yow-Sien Lin; Yijuang Chern
Journal:  Cell Mol Life Sci       Date:  2012-05-25       Impact factor: 9.261

3.  Nicotinamide improves motor deficits and upregulates PGC-1α and BDNF gene expression in a mouse model of Huntington's disease.

Authors:  Tyisha Hathorn; Abigail Snyder-Keller; Anne Messer
Journal:  Neurobiol Dis       Date:  2010-08-22       Impact factor: 5.996

Review 4.  Differential vulnerability of neurons in Huntington's disease: the role of cell type-specific features.

Authors:  Ina Han; YiMei You; Jeffrey H Kordower; Scott T Brady; Gerardo A Morfini
Journal:  J Neurochem       Date:  2010-03-17       Impact factor: 5.372

5.  Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation.

Authors:  Rajnish K Chaturvedi; Noel Y Calingasan; Lichuan Yang; Thomas Hennessey; Ashu Johri; M Flint Beal
Journal:  Hum Mol Genet       Date:  2010-06-07       Impact factor: 6.150

6.  Huntington's disease and mitochondrial alterations: emphasis on experimental models.

Authors:  Verónica Pérez-De la Cruz; Paul Carrillo-Mora; Abel Santamaría
Journal:  J Bioenerg Biomembr       Date:  2010-06       Impact factor: 2.945

Review 7.  Current understanding on the pathogenesis of polyglutamine diseases.

Authors:  Xiao-Hui He; Fang Lin; Zheng-Hong Qin
Journal:  Neurosci Bull       Date:  2010-06       Impact factor: 5.203

Review 8.  Increased mitochondrial fission and neuronal dysfunction in Huntington's disease: implications for molecular inhibitors of excessive mitochondrial fission.

Authors:  P Hemachandra Reddy
Journal:  Drug Discov Today       Date:  2014-03-28       Impact factor: 7.851

Review 9.  Mitochondrial approaches for neuroprotection.

Authors:  Rajnish K Chaturvedi; M Flint Beal
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

Review 10.  Mitochondrial calcium function and dysfunction in the central nervous system.

Authors:  David G Nicholls
Journal:  Biochim Biophys Acta       Date:  2009-03-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.